CG Oncology President & COO Bellete to depart June 30; CEO Kuan becomes President

CG Oncology, Inc.

Ambaw Bellete, President & COO, agreed to separation effective June 30, 2026; severance per existing employment agreement.
Arthur Kuan appointed as President in addition to his other roles, effective upon Bellete's departure.
Company has initiated a search for a Chief Commercial Officer.
No reason for departure given; transition appears orderly.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Arthur Kuan

President

CGON · CG Oncology, Inc.

Effective: 2026-06-30
Filed: May 26, 2026, 8:00 AM ET

On May 20, 2026, the Company’s Board of Directors also approved the appointment of Arthur Kuan as President of the Company, in addition to his other positions, in connection with Mr. Bellete’s separation.

Departed

Ambaw Bellete

President & Chief Operating Officer

CGON · CG Oncology, Inc.

Effective: 2026-06-30
Successor: Arthur Kuan
Filed: May 26, 2026, 8:00 AM ET

On May 20, 2026, CG Oncology, Inc. (the “ Company ”) and Ambaw Bellete, the Company’s President & Chief Operating Officer of the Company, agreed to his separation from the Company to be effective June 30, 2026.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Arthur Kuan was appointed as President at CG Oncology, Inc..

Action: appointed
Role: President

Exact text from the filing

On May 20, 2026, the Company’s Board of Directors also approved the appointment of Arthur Kuan as President of the Company, in addition to his other positions, in connection with Mr. Bellete’s separation.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Ambaw Bellete departed as President & Chief Operating Officer at CG Oncology, Inc..

Action: agreed to his separation
Role: President & Chief Operating Officer

Exact text from the filing

On May 20, 2026, CG Oncology, Inc. (the “ Company ”) and Ambaw Bellete, the Company’s President & Chief Operating Officer of the Company, agreed to his separation from the Company to be effective June 30, 2026.

View on SEC.gov

CG Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-237908

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.